And our €“ we expect to bill them about roughly $80 to $100 per month. So that’s essentially we’re splitting that $200 between us and the practice. Now, I’m glad you mentioned this, because I forgot to mention one other revenue opportunity for the practice, because our system facilitates telehealth, they can also bill for telehealth visits in addition to the remote patient monitoring. So if there is a €“ if the patient has some illness or they have something that needs to be worked out to decide whether they need to come to the hospital or something like that, and they engage in a telehealth visit, they can bill in addition to that. But hopefully, it’s clear now that there’s a distinction between telehealth billing and remote patient monitoring.
By the way, just one other thing since you got me in the weeds of this Ross, which is that the remote patient monitoring codes are well established prior to COVID. They’re not subject to extraordinary statutory statutes that were enacted during COVID. The telehealth, although, it has been updated and renewed is a little bit less firm ground, because much of that was escalated as a result of COVID. I mean, the expectations are that it’ll remain, but that still will require governmental action.
Ross Osborn: Okay. That’s very helpful. Thank you.
Lishan Aklog: Yeah. Thanks, Ross.
Operator: Our next question today comes from Frank Takkinen with Lake Street Capital.
Frank Takkinen: Hi, good morning.
Lishan Aklog: Hi, Frank.
Frank Takkinen: Good morning. Thanks for taking the questions. Congrats on all the progress. Wanted to start with one on Veris and specifically the commercialization efforts. Maybe kind of lay the playing field for how you guys expect to commercialize that platform throughout 2023. And then how does that change once the implantables approaching FDA 510(k) clearance order actually receives the clearance?
Lishan Aklog: That’s a great question. So let’s start with the software platform and the various box connected devices. So our model is fairly straightforward. We got €“ we have a commercial team that calls on, that builds a pipeline and calls on oncology practices. Our Chief Commercial Officer has a long history of calling on such practices. We’re focusing initially as I mentioned on practices that have already demonstrated that they sort of get it, and they participated in value-based model such as the current EOM model and prior OCM model. And so that’s where we’re starting. And however, we have engagements with larger entities, large medical centers, and we look forward to starting the process with large cancer centers although as always the case, those are much longer, much, much longer lead time.
So we €“ it starts with an engagement typically at the clinician level and getting clinician buy-in that the response has been positive. And one of the things that we’ve learned in our early experience, which is a bit of a surprise relative to where we, what our expectations were when we first acquired the prior company Oncodisc, is that the conversations quickly moved to RPM. We thought that, that the conversations would focus initially on the clinical benefit and being able to pick up our early complications and so forth. And what we’re finding is that likely as a result of the pandemic and other technologies, that the practices are very focused. I mean, it’s sort of typically they’ll come in and say, they’ll just say, Hey, is this an RPM thing, thing my practice manager told me we need to look into this, right?
